The Potential Role of SGLT2 Inhibitors in the Treatment of Depression: Mechanisms and Clinical Prospects - PubMed
3 hours ago
- #depression
- #neuroprotection
- #SGLT2 inhibitors
- Major depressive disorder (MDD) is a high-burden psychiatric illness with rising global prevalence and suicide risk.
- Traditional treatments like SSRIs have limitations, prompting exploration of new strategies.
- MDD pathogenesis involves neuroinflammation, oxidative stress, HPA axis dysfunction, and impaired cerebral energy metabolism.
- There is a bidirectional link between MDD and type 2 diabetes (T2DM), with shared pathological processes.
- SGLT2 inhibitors (SGLT2i) show potential in treating MDD by targeting neuroinflammation, oxidative stress, and synaptic plasticity.
- Current evidence for SGLT2i in psychiatry is early-stage, with promising preclinical and observational studies.
- SGLT2i may cause adverse effects like sleep disturbances and anxiety, requiring cautious use.
- Lack of prospective randomized controlled trials with depression improvement as the primary endpoint remains a gap.
- This review highlights SGLT2i's therapeutic potential for comorbid MDD and T2DM patients.